Product Information
LAMIVUDINE 300 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $1.3483 per EA under NDC 64380071104. Its NADAC has been published 347 times since Sep 12, 2018.
Strength
300 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380071104
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA090457On Market Since
10/19/2018
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 300 MG TABLET has been published 347 times since Sep 12, 2018, and over the history we have for it it has declined 45.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3483 per EA |
|---|---|
| All-time high | $2.4792 (Oct 10, 2018) |
| All-time low | $1.1052 (Jan 22, 2020) |
| 52-week high | $1.5066 |
| 52-week low | $1.2525 |
| Median price | $1.3777 |
| Average price | $1.5423 |
| Largest weekly change | +54.2% (Feb 17, 2021) |
| Weeks tracked | 347 |
| Tracking since | Sep 12, 2018 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of LAMIVUDINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 300 MG TABLET, manufactured by Strides Pharma Inc., is $1.3483 per EA (NDC 64380071104), effective Jun 24, 2026.
How has the price of LAMIVUDINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 300 MG TABLET has declined 45.6%. It has been tracked across 347 weekly CMS publications since Sep 12, 2018.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 300 MG TABLET?
Since Sep 12, 2018, the NADAC for LAMIVUDINE 300 MG TABLET has ranged from a low of $1.1052 (Jan 22, 2020) to a high of $2.4792 (Oct 10, 2018), with a median of $1.3777 per EA.
Are there cheaper alternatives to LAMIVUDINE 300 MG TABLET?
Yes. 3 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LAMIVUDINE 300 MG TABLET, is $1.3014 per EA — about 3% below LAMIVUDINE 300 MG TABLET.
Who manufactures LAMIVUDINE 300 MG TABLET?
LAMIVUDINE 300 MG TABLET (NDC 64380071104) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification